EPIX
ESSA Pharma Inc.Company Information
- Company Name
- ESSA Pharma Inc.
- CIK
- CIK0001633932
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- EPIX: None
- Fiscal Year End
- September 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EPIX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-12-14
- Last sale
- 2025-08-05
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 7,883,209
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 22,423,834
- Shares outstanding
- 44,388,550
- Ownership
- 50.52%
Earnings Market Reaction
- Filing date
- —
- Price on filing date
- —
- 1-month reaction
- —
- 3-month reaction
- —
Balance Sheet
Values in millions ($)| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 86 | 86 | 93 | 104 | 86 | 92 | 35 | 34 | 38 | 44 | 51 | 57 | ||||||
| Short Term Investments | 24 | 28 | 27 | 23 | 45 | 44 | 107 | 114 | 114 | 113 | 112 | 110 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 111 | 115 | 122 | 128 | 132 | 137 | 144 | 149 | 153 | 158 | 165 | 169 | ||||||
| Receivables Net Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | ||||||
| Deposits Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 111 | 115 | 123 | 128 | 133 | 138 | 144 | 149 | 154 | 159 | 165 | 170 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 2 | 2 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 2 | 3 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 2 | 2 | 4 | 3 | 4 | 4 | 4 | 3 | 3 | 2 | 3 | 2 | ||||||
| Operating Lease Liability Current | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 3 | 2 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Value | 280 | 280 | 280 | 280 | 280 | 280 | 279 | 278 | 278 | 278 | 278 | 278 | ||||||
| Additional Paid In Capital | 58 | 59 | 58 | 55 | 53 | 50 | 50 | 49 | 48 | 47 | 46 | 44 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 109 | 114 | 119 | 125 | 129 | 133 | 141 | 146 | 150 | 156 | 162 | 167 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -227 | -223 | -217 | -208 | -202 | -194 | -185 | -179 | -174 | -167 | -160 | -153 | ||||||
| Liabilities And Stockholders Equity | 111 | 115 | 123 | 128 | 133 | 138 | 144 | 149 | 154 | 159 | 165 | 170 | ||||||
| Common Stock Shares Issued | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | ||||||
| Shares Outstanding | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialESSA Pharma Inc. (EPIX) — SEC Financial Statements & Analysis
ESSA Pharma Inc. (EPIX) is a pharmaceutical preparations company, incorporated in A1. ESSA Pharma Inc. trades on None as: EPIX. ESSA Pharma Inc. (EPIX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-13. Based on that filing, On profitability, ESSA Pharma Inc. posts a Return on Equity (ROE) of -21.25%, a Return on Assets (ROA) of -20.78%, and a Return on Invested Capital (ROIC) of -76.76%. Per share, it reports EPS of $-0.57, diluted EPS of $-0.57, free cash flow per share of $-0.47, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -8.69% year-over-year and EPS growth of -8.73% year-over-year. On the balance sheet, it maintains a current ratio of 69.07x, a quick ratio of 68.84x, working capital of $108.90M, a debt-to-equity ratio of 0.01x, a debt ratio of 0.01, free cash flow of $-20.88M (TTM), and net debt of $-85.95M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.57
- ROE TTM
- -21.25%
- ROA TTM
- -20.78%
- Debt To Equity
- 0.01x
- Free Cash Flow TTM
- $-20.88M
Data as of 2025-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ESSA Pharma Inc. in?
ESSA Pharma Inc. (EPIX) operates in the Pharmaceutical Preparations industry.
What exchange does EPIX trade on?
ESSA Pharma Inc. (EPIX) trades on the None.
Where is ESSA Pharma Inc. incorporated?
ESSA Pharma Inc. is incorporated in British Columbia, Canada.
When was ESSA Pharma Inc. (EPIX)'s most recent SEC filing?
ESSA Pharma Inc. (EPIX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-13.
What is EPIX's EPS (earnings per share)?
ESSA Pharma Inc. (EPIX)'s trailing twelve month EPS is $-0.57 as of 2025-06-30.
What is EPIX's ROE (return on equity)?
ESSA Pharma Inc. (EPIX)'s trailing twelve month Return on Equity (ROE) is -21.25% as of 2025-06-30.
What is EPIX's ROA (return on assets)?
ESSA Pharma Inc. (EPIX)'s trailing twelve month Return on Assets (ROA) is -20.78% as of 2025-06-30.
What is EPIX's ROIC (return on invested capital)?
ESSA Pharma Inc. (EPIX)'s trailing twelve month Return on Invested Capital (ROIC) is -76.76% as of 2025-06-30.